Preclinical Evaluation of 99m Tc-Labeled LHRH Analog as Cancer Receptor Imaging
Oncology · 2025
DOI: 10.1159/000542823 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Lucía Alfaya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiopharmaceuticals, Gonadotropin-Releasing Hormone, Organotechnetium Compounds. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Introduction
Breast cancer is the main cause of cancer-related mortality in women in the developed world. In particular, receptors of luteinizing hormone-releasing hormone (LHRH or GnRH) are overexpressed in this malignant disease. The aim of this study was to develop a new molecular probe [99mTc]Tc-HYNIC-GSG-LHRH(d-Lys6)/tricine/nicotinic acid (NA) as a novel molecular imaging agent for breast cancer.
Methods
HYNIC-GSG-LHRH(D-Lys6) was acquired and radiolabeled with [99mTc]Tc. Radiochemical purity and stability under different conditions were evaluated by instant thin-layer chromatography (ITLC) and high-performance liquid chromatography. Lipophilicity was determined by the partition coefficient test. In vitro cell binding studies were performed in different human and mice breast cancer cell lines (MDA-MB-231, MDA-MB-435, MCF-7, BT474, and 4T1) as well as in normal murine fibroblasts (NIH-3T3) and CHO-K1 as a negative control. Biodistribution studies were performed in normal Balb/c mice and 4T1 tumor-bearing Balb/c mice up to 6 h post-injection (pi). SPECT/CT images were performed in 4T1 tumor-bearing Balb/c mice up to 5 h pi. Results: [99mTc]Tc-HYNIC-GSG-LHRH(d-Lys6)/tricine/NA complex was labeled with a high radiochemical purity (>98%) and remained stable for up to 4 h. It exhibited good hydrophilicity (log p = −2.82 ± 0.04) and also demonstrated significant and specific binding across all evaluated breast cancer cell lines. Biodistribution studies showed a high renal clearance and low nonspecific binding (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.
- Programa de Posgrado, Facultad de Química, Universidad de la República, Montevideo, Uruguay.
- Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay.
- Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay, pcabral@cin.edu.uy.
Zitieren
APA
Alfaya, L., Camacho, X., Cabrera, M., Tassano, M., Savio, E., Reyes, L., Paolino, A., García, M. F., Fernández, M., Gambini, J. P., & Cabral, P. (2025). Preclinical Evaluation of 99m Tc-Labeled LHRH Analog as Cancer Receptor Imaging. Oncology. https://doi.org/10.1159/000542823
Vancouver
Alfaya L, Camacho X, Cabrera M, Tassano M, Savio E, Reyes L, et al. Preclinical Evaluation of 99m Tc-Labeled LHRH Analog as Cancer Receptor Imaging. Oncology. 2025. doi:10.1159/000542823
BibTeX
@article{Alfaya2025,
author = {Alfaya, Lucía and Camacho, Ximena and Cabrera, Mirel and Tassano, Marcos and Savio, Eduardo and Reyes, Laura and Paolino, Andrea and García, María Fernanda and Fernández, Marcelo and Gambini, Juan Pablo and Cabral, Pablo},
title = {Preclinical Evaluation of 99m Tc-Labeled LHRH Analog as Cancer Receptor Imaging},
journal = {Oncology},
year = {2025},
doi = {10.1159/000542823}
}
EUVIMED